CD274 and cancer: In particular, three immune checkpoint pathways, namely programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 CTLA-4, have emerged as target for cancer therapeutics.